GLP1R and Alzheimer disease: Recent evidence has indicated a significant correlation between type 2 diabetes (T2DM) and AD,6 and glucagon‐like peptide‐1 (GLP‐1), a therapeutic drug of T2DM, has been shown to impart significant neuroprotection.